The global human insulin market is highly consolidated with few Tier I players
Novo Nordisk, the Denmark based company, has emerged as the market leader in the global human insulin market and is likely to maintain its leadership position in the coming years. Novo Nordisk entered the human biopharmaceutical market in 1923. It is engaged in the development, production, and marketing of pharmaceutical and biotechnology products. The two key segments of Novo Nordisk are diabetes care and biopharmaceuticals. The Danish giant has a strong anti-diabetic product portfolio with blockbuster products such as Levemir and NovoRapid.
The key players in the market are Novo Nordisk (Denmark), Eli Lilly (U.S), Sanofi Aventis (France), Biocon (India), Julphar (U.A.E), Wockhardt (India), SemBioSys (Canada), and GSK (U.K.).
The diabetes care segment generated more than three quarter of the company's total revenue in 2013. The company has strengthened its position by means of introducing human insulin for each type ranging from short acting human insulin to rapid acting human insulin, and attributed to be the broadest product portfolio with 7 human insulin drugs that are distributed to more than 180 countries across the world. Apart from this, the company has seven novel human insulins under pipeline and has filed several approvals in Europe and U.S. To gain the maximum market share, the company has been aggressively investing in research and development that helps in launching of new products in the market.
New Drug Approval, coupled with product launch was the predominant growth strategy followed by players in this market. New Drug Approval accounted for a ~66% share of the total developments in this market; collaborations, agreements, and partnerships together accounted for the second largest share of 24%. During 2011 to 2014, the industry witnessed more than 10 new drug approval filing by key players whereas, 5-6 agreements and collaboration undertook between players in the market.
Related Reports:
Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019
Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
